R208
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 128
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.380
- HEDGEHOG_SIGNALING+0.320
- BILE_ACID_METABOLISM+0.290
- ADIPOGENESIS+0.240
- FATTY_ACID_METABOLISM+0.240
- ANGIOGENESIS+0.220
- XENOBIOTIC_METABOLISM+0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- APICAL_SURFACE+0.180
- PEROXISOME+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.460
- E2F_TARGETS-0.400
- MYC_TARGETS_V1-0.390
- ALLOGRAFT_REJECTION-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- TGF_BETA_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- G2M_CHECKPOINT-0.330
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617843 | — | B | 0.834 |
| 2 | ERR2208949 | — | — | 0.810 |
| 3 | SRR1332796 | GTEX | — | 0.810 |
| 4 | SRR8518125 | — | F | 0.807 |
| 5 | SRR1359123 | GTEX | — | 0.804 |
| 6 | ULC0515T_S15 | — | cohortA1 | 0.801 |
| 7 | C3L-01890 | — | cohortA2 | 0.800 |
| 8 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.798 |
| 9 | TCGA-CF-A7I0-01A-22R-A352-07 | — | — | 0.796 |
| 10 | SRR1445347 | GTEX | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |